Novartis increases sales of Genmab-developed sclerosis drug
On Wednesday, Novartis presented its full-year financial report, including sales figures for sclerosis drug Kesimpta, which was originally developed in Genmab’s labs.
by marketwire, translated by daniel pedersen
Genmab’s Swiss partner, Novartis, continues to push sales for sclerosis drug Kesimpta.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novartis beats expectations for third quarter
For subscribers
